In December 2017, the Russian commercial market of medicinal products was worth 69.3 billion rubles (including VAT). Compared to November 2017, the market volume grew by 7.5%. On a year-over-year basis, the sales increased by 2.4%.
“In December 2017, the average price for a pack of medicines on the Russian commercial market declined by 0.4% compared to the previous month and amounted to 149.7 rubles,” said Sergey Shulyak, the expert of pharmaceutical market and General Director of DSM Group.
In terms of price segments, the structure of commercial market for medicinal products has changed in December 2017 following an increase in the share of higher price segment drugs compared to the same period of 2016.
For December 2017, 58.8% of the drugs sold on the market were manufactured in Russia (in physical terms). But, due to their lower price comparing to imported medicines, they accounted for 29.8% of the market in value terms.
Over the same period, 32.4% of commercial market segment were the prescription drugs and 67.6% were the OTC drugs, while in value terms the market is virtually divided in half (50.7% and 49.3%, respectively).
In terms of sales, the ranking of companies for December 2017 was topped by Bayer; the second rank is held by Novartis and the third by Sanofi.